TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01039883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albaconazole tablet 400mg
Description: Albaconazole tablet 400mg single dose, then four albaconazole capsule 100mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albaconazole 100mg capsules, then albaconazole 400mg tablet
Description: Four albaconazole capsule 100mg single dose, then albaconazole tablet 400mg single dose
Study: NCT03245489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg intravenous (IV) over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg intravenous (IV) over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 75mg/day oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 75mg/day oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: 81mg/day oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: 81mg/day oral
Study: NCT01215097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once a day
Study: NCT02411097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femoral nerve block
Description: use the nerve stimulator,the femoral nerve block will be administered before or after the surgery
Study: NCT01849731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face-to-face
Description: is carried out by the GPs during the clinic visit and consists of seven visits, one every three months. Each session consists of completing a diabetes care record sheet (DCRS) together with the patient. The DCRS consists of two parts: Five questions on self-care activities in the last three months and a graph with previously measured HbA1c levels. This information is completed at each session, resulting in a graph showing the evolution of glycaemic control related to self-care activities. The DCRS is explained patients, emphasising the relationship between self-care and glycemic control. At the end of the session, patients are given a copy of the DCRS and suggested to show it and discuss it with their relatives.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face-to-face intervention plus telephone reinforcement
Description: In this group patients receive the above described intervention A plus a telephone reinforcement It consists on five telephone calls lasting about 10 minutes each, to provide advice on carrying out physical exercise and eating a balanced diet and to encourage the use of health services related to diabetes control. Any problems or doubts that patients have stemming from any aspect of diabetes care are also discussed. Telephone reinforcement is carried out by a professional who has previously been trained in promoting T2DM self-management and in motivational interviewing techniques.
Study: NCT02633696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silybin phosphatidylcholine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Legalón SIL
Study: NCT04517175

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry
Description: Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67.

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry
Description: Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67.

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry
Description: Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67.
Study: NCT02541604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab was administered as IV infusion (maximum 1200 mg) on Day 1 of each 21-day cycle.
Study: NCT04216797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam Tablets
Description: Participants will be randomly assigned to either an oral or rectal administration of once daily 10 mg diazepam tablets for four weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam Tablets
Description: Participants will be randomly assigned to either an oral or rectal administration of once daily 10 mg diazepam tablets for four weeks.
Study: NCT00256568

Intervention type: BEHAVIORAL
Intervention: reporting system
Description: Nurses and office staff were asked to report all communications with community pharmacists regarding prescription problems
Study: NCT04752241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior Mesenteric Artery Preservation
Description: Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior Mesenteric Artery Ligation
Description: Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
Study: NCT01989494

Intervention type: DEVICE
Intervention: Pedometer
Description: All groups will receive a pedometer to measure their daily steps

Intervention type: DEVICE
Intervention: Pedometer
Description: All groups will receive a pedometer to measure their daily steps
Study: NCT03534180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT04154813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: The initial dose of 25mg/d is rapidly increased to the target dose (100mg/d) or below the maximum tolerable dose if the patient can tolerate it.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine was increased from 20mg/d to the target dose (60mg/d) or below the maximum tolerable dose within 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine was increased from 20mg/d to the target dose (60mg/d) or below the maximum tolerable dose within 2 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy (CBT)
Description: CBT psychotherapy, once a week for three months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dialectical behavior therapy (DBT)
Description: DBT psychotherapy,once a week for three months.
Study: NCT03220321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PICN (VITA Enamic) hybrid abutment crown
Description: Hybrid ceramic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lithium disilicate (IPS e.max) hybrid abutment crown
Description: Glass ceramic
Study: NCT04288284

Intervention type: PROCEDURE
Intervention: Curative resection of colorectal cancer

Intervention type: PROCEDURE
Intervention: Curative resection of colorectal cancer
Study: NCT00746512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 15 mg
Description: Prednisone 15 mg tablets once daily for 15 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Prednisone placebo tablets once daily for 15 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 7.5 mg
Description: Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Over-Encapsulated Tablets
Description: Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days
Study: NCT02745080

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
Study: NCT02757417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium fluorescein

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenazopyridine
Study: NCT04606446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07248144
Description: KAT6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07248144
Description: KAT6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07248144
Description: KAT6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07248144
Description: KAT6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07248144
Description: KAT6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07248144
Description: KAT6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07248144
Description: KAT6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07248144
Description: KAT6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Endocrine Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Endocrine Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Endocrine Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Endocrine Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Endocrine Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK4/6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor
Study: NCT03216824

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dressing
Description: A dressing is maintained on the CVAD exit site.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-Dressing
Description: The CVAD exit site is not covered with a dressing.
Study: NCT04077788

Intervention type: OTHER
Intervention: muscle energy technique
Description: Muscle energy technique:~1. Application of MET for bone of pelvis:~   I) Pubis:~  1. Cranial Os pubis.~  2. Caudal os pubis.~   II) ileum:~  1. Anterior ileum.~  2. Posterior ileum.~  3. External Rotation (In flare) Lesion.~  4. Internal Rotation (Out flare) Lesion.~   III) sacrum:~  1. Forward torsion of sacrum.~  2. Backward torsion of sacrum.~2. Muscle energy technique for specific muscles of pelvis and spine:~   1. Stretch of the Psoas Major.~  2. Stretch of the paravertebral muscle.~  3. Stretch of the piriforms.

Intervention type: OTHER
Intervention: muscle energy technique
Description: Muscle energy technique:~1. Application of MET for bone of pelvis:~   I) Pubis:~  1. Cranial Os pubis.~  2. Caudal os pubis.~   II) ileum:~  1. Anterior ileum.~  2. Posterior ileum.~  3. External Rotation (In flare) Lesion.~  4. Internal Rotation (Out flare) Lesion.~   III) sacrum:~  1. Forward torsion of sacrum.~  2. Backward torsion of sacrum.~2. Muscle energy technique for specific muscles of pelvis and spine:~   1. Stretch of the Psoas Major.~  2. Stretch of the paravertebral muscle.~  3. Stretch of the piriforms.
Study: NCT00106899

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI scans

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI scans

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI scans

Intervention type: PROCEDURE
Intervention: Positron Emission Tomography (PET)
Description: PET scans

Intervention type: PROCEDURE
Intervention: Positron Emission Tomography (PET)
Description: PET scans

Intervention type: PROCEDURE
Intervention: Positron Emission Tomography (PET)
Description: PET scans

Intervention type: PROCEDURE
Intervention: Lumbar Puncture (LP)
Description: collection of cerebrospinal fluid

Intervention type: PROCEDURE
Intervention: Lumbar Puncture (LP)
Description: collection of cerebrospinal fluid

Intervention type: PROCEDURE
Intervention: Lumbar Puncture (LP)
Description: collection of cerebrospinal fluid
Study: NCT03817697

Intervention type: OTHER
Intervention: Questionnaire
Description: The socio-demographic characteristics of patients, their current and past drug use as well as their knowledge of hepatitis B and vaccination, will be collected via a questionnaire, conducted by the service's addictologists at the beginning of the consultation.
Study: NCT02509026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg subcutaneous, once weekly, 24 weeks
Study: NCT02499757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flavor and sweetener
Description: maltol added as sweetener to e-cigarette with flavor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flavor and nicotine
Description: 12 mg of nicotine added to e-cigarette with flavor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flavor, nicotine and sweetener
Description: 12 mg nicotine and maltol (sweetener) added to e-cigarette with flavor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flavor
Description: flavored e-cigarette stand alone without added nicotine and maltol (sweetener)
Study: NCT04247867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medium cut-off (MCO) dialysis membrane
Description: Medium cut-off dialysis (MCO) membrane is a dialysis membrane with a higher molecular weight retention onset and similar cut-off as standard high-flux dialysis membranes. It is capable of providing increased clearance of medium sized uremic toxins and some plasma proteins (cytokines, inflammatory mediators).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary fiber mixture (Plantago Psyllium and Inulin)
Description: Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber mixture (Plantago Psyllium and Inulin)
Description: Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium propionate
Description: Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium propionate
Description: Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.
Study: NCT01379508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbivudine
Description: 600 mg film-coated tablets taken as 600 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir disoproxil fumarate
Description: 300 mg tablets taken as 300 mg once daily
Study: NCT00892346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single ASCT with Thalidomide maintenance
Description: Single ASCT with Thalidomide maintenance:~1. Single Autologous Stem Cell Transplantation: conditioning with Melphalan 200mg/m2 (iv)~2. Thalidomide maintenance: starting from D60 after transplantation at 100-200mg daily (Oral)
Study: NCT00942227

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy rehabilitation
Description: Extension oriented exercises. Subjects will be instructed in a progression of extension oriented exercises for the lumbar spine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy rehabilitation
Description: Mechanical lumbar traction will be applied with subjects in prone utilizing 40-60% of subject's body weight to create a distraction force in the lumbar spine. Following traction, subjects will be instructed in a progression of extension oriented exercises and manual therapy to increase extension as described for the comparator group.
Study: NCT04556799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computer-assisted surgery
Description: derotation osteotomy with the aid of 3D osteotomy template and computer-assisted simulated surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional osteotomy
Description: traditional osteotomy without the aid of 3D osteotomy template
Study: NCT01512511

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nitrous oxide use for pneumoperitoneum creation
Description: use nitrous oxide for create pneumoperitoneum in laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nitrous oxide use for pneumoperitoneum creation
Description: use nitrous oxide for create pneumoperitoneum in laparoscopic cholecystectomy
Study: NCT06464822

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: weight control procedures, including intragastric balloon (IGT) \[5\], laparoscopic adjustable gastric banding (LAGB) \[6\], laparoscopic gastric bypass (LGB) operation and laparoscopic sleeve gastrectomy (LSG)
Study: NCT00895206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: individual adapted immunosuppression
Description: individual adapted immunosuppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: golden standard therapy
Description: golden standard therapy
Study: NCT04695717

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IVACFLU-S
Description: The Seasonal Inactivated, Split Virion, Trivalent Influenza Vaccine (TIV) were purified by the method of super centrifugation to create gradient segments in sucrose sugar produced by IVAC, or placebo produced by IVAC. Vaccines are produced on eggs, inactivated with formaldehyde. The dose of the vaccine tested was 15 mcg of HA for each antigen component in 0.5 ml.~The influenza virus strains used to produce the 2020-2021 seasonal vaccine will also be provided by the NIBSC, which will be used according to WHO's recommendation, which is expected to include the following Southern Hemisphere strains:~Influenza A / H1N1 strain: Recombinant strain IVR-190 44250 E12 of the strain (A / Brisbane / 02/2018).~Influenza strain A / H3N2: strain IVR-197 (H3N2) 44850 E14 recombinant strain (A / South Australia / 34/2019).~Flu strain B (B / Washington / February 2019).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IVACFLU-S
Description: The Seasonal Inactivated, Split Virion, Trivalent Influenza Vaccine (TIV) were purified by the method of super centrifugation to create gradient segments in sucrose sugar produced by IVAC, or placebo produced by IVAC. Vaccines are produced on eggs, inactivated with formaldehyde. The dose of the vaccine tested was 15 mcg of HA for each antigen component in 0.5 ml.~The influenza virus strains used to produce the 2020-2021 seasonal vaccine will also be provided by the NIBSC, which will be used according to WHO's recommendation, which is expected to include the following Southern Hemisphere strains:~Influenza A / H1N1 strain: Recombinant strain IVR-190 44250 E12 of the strain (A / Brisbane / 02/2018).~Influenza strain A / H3N2: strain IVR-197 (H3N2) 44850 E14 recombinant strain (A / South Australia / 34/2019).~Flu strain B (B / Washington / February 2019).
Study: NCT02109185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasonex® Nasal Spray, 50 μg/actuation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasonex® Nasal Spray Suspnsn, 50 μg/actuation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray, 50 μL/actuation
Study: NCT03795246

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Consultation
Description: Consultation in oncology: collection of oncological data and ongoing cancer treatments, clinical exam Consultation in gynecology: collection of gynecological data, contraception and reproductive medicine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological Test
Description: Blood test:~* FSH, LH, E2 and AMH~* 4 tubes of 7 mL

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic Ultrasound
Description: Antral Follicles Count
Study: NCT02130791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep
Study: NCT01933568

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: combined CFRT and SABR with concurrent cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: combined CFRT and SABR with concurrent cisplatin
Study: NCT01440192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDA001 (cenplacel-L)
Description: 1 unit PDA001 (approximately 200 x 106 cells) IV on Days 1 \& 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDA001 (cenplacel-L)
Description: 1 unit PDA001 (approximately 200 x 106 cells) IV on Days 1 \& 8
Study: NCT04475887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Carboxymaltose
Description: see above

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: see above
Study: NCT03055130

Intervention type: OTHER
Intervention: Thinprep Cytology Test (TCT) and HPV infection types were tested by gynecologist

Intervention type: OTHER
Intervention: Thinprep Cytology Test (TCT) and HPV infection types were tested by gynecologist
Study: NCT04730219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab paclitaxel 200mg will be administered on Day 2 every 3 weeks for 3 cycles
Study: NCT00990704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: Intravenous administration 3 times a week immediately before completion of dialysis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maxacalcitol
Description: Intravenous administration 3 times a week immediately before completion of dialysis
Study: NCT02897440

Intervention type: PROCEDURE
Intervention: Full Repairng of soft tissue surrounding the hip
Description: Full repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.

Intervention type: PROCEDURE
Intervention: Partial Repairng of soft tissue surrounding the hip
Description: Partial repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
Study: NCT00714727

Intervention type: PROCEDURE
Group type: OTHER
Intervention: acupuncture
Description: 8 weeks of acupuncture, starting with twice a week for 4 weeks, followed by once a week for 4 weeks, using 8 standardized, bilateral acupuncture points.